egtazic acid has been researched along with dp-b99 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ioffe, V; Kalendarev, T; Zupkovitz, G | 1 |
| Pop, E | 1 |
| Yeung, PK | 1 |
| Angel, I; Kozak, A; Rosenberg, G | 1 |
| Shah, S; Tear, S | 1 |
| Bornstein, NM; Diener, HC; Kozak, A; Lampl, Y; Rosenberg, G; Schneider, D | 1 |
| Barkalifa, R; Friedman, JE; Hershfinkel, M; Kozak, A; Sekler, I | 1 |
| Caraco, Y; Marshall, LS; Rosenberg, G | 1 |
| Bornstein, N; Diener, HC; Gorelick, PB; Lees, K; Rosenberg, G; Shuaib, A | 1 |
| Arba, F; Balami, JS; Buchan, AM; Kleinschnitz, C; Minnerup, J; Sutherland, BA | 1 |
| Bornstein, N; Diener, HC; Gorelick, PB; Lees, KR; Rosenberg, G; Shuaib, A | 1 |
| Bakshi, RP; Friedman, JE; Grab, DJ; Nenortas, E; Nikolskaia, OV; Shapiro, TA | 1 |
| Figiel, I; Kaczmarek, L; Konopka, A; Korkotian, E; Melikyan, A; Rutkowska-Wlodarczyk, I; Wilczyński, GM; Yeghiazaryan, M | 1 |
2 review(s) available for egtazic acid and dp-b99
| Article | Year |
|---|---|
DP-b99 (D-Pharm).
Topics: Animals; Brain Ischemia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Bypass; Craniocerebral Trauma; Egtazic Acid; Humans; Nervous System Diseases; Neuroprotective Agents; Structure-Activity Relationship | 2004 |
Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Chelating Agents; Clinical Trials as Topic; Combined Modality Therapy; Diffusion of Innovation; Disease Models, Animal; Drug Evaluation, Preclinical; Egtazic Acid; Hematopoietic Cell Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnesium; Minocycline; NADPH Oxidases; Neuroprotective Agents; Pregnatrienes; Serum Albumin; Stroke; Thrombolytic Therapy; Translational Research, Biomedical | 2012 |
5 trial(s) available for egtazic acid and dp-b99
| Article | Year |
|---|---|
Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Egtazic Acid; Electrocardiography; Heart Rate; Humans; Male; Nootropic Agents | 2005 |
DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Brain; Brain Infarction; Brain Ischemia; Cell Membrane; Chelating Agents; Cytoprotection; Double-Blind Method; Egtazic Acid; Emergency Medical Services; Female; Humans; Injections, Intravenous; Ions; Male; Metals; Middle Aged; Neuroprotective Agents; Placebos; Treatment Outcome | 2008 |
The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro.
Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Egtazic Acid; Genotype; Humans; Male; Neuroprotective Agents; Warfarin; Young Adult | 2011 |
The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chelating Agents; Double-Blind Method; Egtazic Acid; Female; Humans; Male; Middle Aged; Research Design; Stroke; Young Adult | 2011 |
Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Chelating Agents; Dose-Response Relationship, Drug; Double-Blind Method; Egtazic Acid; Endpoint Determination; Female; Humans; Male; Middle Aged; Severity of Illness Index; Stroke; Time Factors; Treatment Outcome | 2013 |
6 other study(ies) available for egtazic acid and dp-b99
| Article | Year |
|---|---|
The unusual gradient elution for reversed phase HPLC of a strong chelator as an active drug substance.
Topics: Chelating Agents; Chromatography, High Pressure Liquid; Egtazic Acid | 2001 |
Trends in neuroprotection.
Topics: Aged; Amlodipine; Animals; Antiparkinson Agents; Apoptosis; Brain Diseases; Calcium Channel Blockers; Cannabinoids; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dopamine Agents; Egtazic Acid; Eye Diseases; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Memantine; Mice; Multicenter Studies as Topic; Neuroprotective Agents; Optic Nerve Diseases; Pregnatrienes; Rats | 2002 |
Progressive neurodegenerative disease and pain.
Topics: Analgesics; Animals; Caprylates; Cognition Disorders; Egtazic Acid; Humans; Neurodegenerative Diseases; Pain; Parkinson Disease; TRPV Cation Channels | 2005 |
The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death.
Topics: Animals; Cell Death; Cell Line; Chelating Agents; Egtazic Acid; Hydrophobic and Hydrophilic Interactions; Intracellular Space; Mice; Neurons; Zinc | 2009 |
Membrane active chelators as novel anti-African trypanosome and anti-malarial drugs.
Topics: Animals; Antimalarials; Egtazic Acid; Molecular Structure; Plasmodium; Trypanocidal Agents; Trypanosoma | 2013 |
DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity.
Topics: Animals; Chelating Agents; Dendritic Spines; Egtazic Acid; Hippocampus; Kainic Acid; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Seizures | 2014 |